Armata Pharmaceuticals, Inc.

AMEX:ARMP

Biotechnology

Healthcare
$2.98 -0.28%

-$0.02 today

Market cap
$110.83M
Beta
1.22
P/E (TTM)
-0.9
EPS (TTM)
-$7.74
52W Low $1.81High $16.34

Volume 0.07M

Average 0.07M

Returns on capital

Armata Pharmaceuticals, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

79.5%

avg -56.1%

ROIC

-43.1%

avg -75.1%

ROA

-226.1%

avg -76.4%

Analysis

ROE is currently the strongest return metric at 79.5% versus its period average of -56.1%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Deborah L. Birx

Chief Executive Officer & DirectorUSD 851.91K69——

Pierre Kyme

Chief Business OfficerUSD 625.75K489.46K0.03%

David House

Chief Financial OfficerUSD 513.31K42——

Peter Hubbard

Vice President of Operations————

Bani Tchekanova

Head of Regulatory Strategy & Operations————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Mar 14, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A-3.8%
+63.0% (5yr)1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Recent growth has been strongest in Revenue at -3.8% over three years. Forward estimates point to Revenue at +63.0% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Armata Pharmaceuticals, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Competitors

Peer companies in the same sector

Health

Questions

Management questions

Common questions about ARMP's management, answered from reported figures.

Who manages ARMP?

Armata Pharmaceuticals, Inc. (ARMP) lists 5 active executives. The top listed executive is Deborah L. Birx, Chief Executive Officer & Director.

Are ARMP insiders buying or selling?

Recent insider activity shows net buying of $195.79M.